Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of BMS-986322 in Healthy Japanese Participants
NCT05546151Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2022
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of lomedeucitinib in plaque psoriasis, sponsored by Bristol Myers Squibb. Primary endpoints: Number of participants with serious adverse events up to 7 weeks, Number of participants with adverse events leading to discontinuation up to 7 weeks and 6 more. Started Sep 2022; status: completed.
02
Drugs
lomedeucitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT05546151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05546151.